Guardant Health, Inc. (GH)

Market Cap	13.29B
Revenue (ttm)	902.57M
Net Income (ttm)	-398.79M
Shares Out	126.04M
EPS (ttm)	-3.21
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,347,789
Open	99.75
Previous Close	100.30
Day's Range	98.23 - 108.06
52-Week Range	29.91 - 110.00
Beta	1.60
Analysts	Strong Buy
Price Target	75.48 (-28.4%)
Earnings Date	Oct 29, 2025

About GH

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company provides precision oncology testing services comprising Guardant360, a panel of genetic tests; Guardant360 LDT that measures 730+ genes and supports all guideline-recommended biomarkers; Guardant360 CDx Test, a liquid biopsy test; Guardant360 Response Test, a blood-only liquid biopsy; Guardant360 TissueNext Test, a tissue-based test with AI-powered PD-L1 detection; GuardantINFINITY Test that p...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Oct 4, 2018
• Employees: 2,021
• Stock Exchange: NASDAQ
• Ticker Symbol: GH
• Website: https://guardanthealth.com

Financial Performance

In 2024, Guardant Health's revenue was $739.02 million, an increase of 31.04% compared to the previous year's $563.95 million. Losses were -$436.37 million, -8.98% less than in 2023.

Analyst Summary

According to 21 analysts, the average rating for GH stock is "Strong Buy." The 12-month stock price target is $75.48, which is a decrease of -28.40% from the latest price.

Price Target

$75.48

(-28.40% downside)

Analyst Consensus: Strong Buy